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sT189I, sV190A, sS193L, sI195M, sW196L, sW196St., 
sS207R, sI208T, sS210E, sF219S, sF220L and sC221G). 
Thirteen (81.2%) of these mutations emerged down-
stream to the MHR. Nine of 16 types of S-gene mutations 
observed with lamivudine therapy were also associated 
with the corresponding changes in the polymerase gene. 
Baseline viral DNA was signifi cantly higher (2,093 vs. 
336 pg/ml; p  ! 0.05) among patients developing S-gene 
mutants and the ETR in them was signifi cantly lower 
[3 of 16 (18.8%) vs. 17 of 41 (41.5%); p  ! 0.05].  Conclusions: 
Naturally occurring S-gene mutations are uncommon 
and are restricted to the ‘a’ determinant region. Muta-
tions develop in about a quarter of the patients on 
 lamivudine therapy, mostly downstream to the MHR. 
They may contribute to non-response to the antiviral 
 therapy. 
 Copyright © 2006 S. Karger AG, Basel 
 Introduction 
 HBV is a hepadnavirus with a genome of 3.2-kb size. 
The genome of HBV has four overlapping open reading 
frames (ORFs: S-, C-, P- and X-ORFs) where surface gene 
overlaps with the catalytic domains of the polymerase (P) 
gene  [1] . Three envelope proteins [large (L), middle (M) 
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 Abstract 
 Background: Besides vaccine escape or immune escape 
hepatitis B virus (HBV) mutants, naturally occurring and 
drug-induced mutations have been reported in the sur-
face gene (S-gene) of HBV.  Aim: To investigate the fre-
quency and profi le of naturally occurring S-gene mu-
tants and the infl uence of long-term lamivudine therapy 
in patients with chronic hepatitis B (CHB).  Materials and 
Methods: 57 patients with histologically proven CHB, on 
lamivudine 100 mg/day for more than 24 months, were 
included. Viral DNA was extracted at baseline and from 
on-therapy serum samples. The region encoding the 
complete major hydrophilic region (MHR) and fl anking 
regions (nucleotides 425–840) of major S-gene that over-
lapped with the viral polymerase was PCR amplifi ed and 
sequenced. End-of-therapy response (ETR) was as-
sessed.  Results: Two (3.5%) patients had naturally occur-
ring HBV mutants, sP127S and sS143L seen in the ‘a’ 
determinant of the S-gene. Following lamivudine thera-
py, 14 of 57 (24.5%) patients developed 16 types of S-
gene mutations (sP120S, sA128V, sS143L, sW182St., 
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and small (S ‘or’ HBsAg)] are synthesized from three in-
frame start codons (ATG) of the pre-S1, pre-S2 and S 
genes of S-ORF  [2] , that are involved in receptor binding 
and viral assembly, and are important targets for im-
mune-mediated virus elimination.  
 The major B-cell epitope cluster of S-protein or HBsAg 
is referred to as the ‘a’ determinant spanning from amino 
acids (aa) 124 to 147, but recent evidence from observed 
natural variation and the complex arrangements of epi-
topes suggests that this epitope cluster could be extended 
up- and downstream to include the entire major hydro-
philic region (MHR, aa 100–160). 
 The humoral immune responses to HBV surface (S) 
protein contributes to the clearance of circulating HBV 
particles, whereas cellular immune responses are respon-
sible for the elimination of infected hepatocytes  [3] . Thus, 
the emergence of variant viruses that escape from hu-
moral or cellular immunity may be implicated in the per-
sistence or progression of HBV infection  [4–6] . 
 Mutations in the entire surface gene could arise in the 
natural course of HBV infection. The prevalence of these 
naturally occurring mutations remains unknown because 
of the lack of comprehensive studies. The surface gene of 
HBV also contains putative HLA class I-restricted cyto-
toxic T lymphocyte (CTL) epitopes  [3] .  In general, viral 
mutations in CTL epitopes could evade cellular immu-
nity and lead to viral persistence  [7, 8] . 
 Specifi c mutations in the catalytic domains of the poly-
merase gene, especially in the YMDD motif of the do-
main C, often appear in relation to the breakthrough dur-
ing antiviral therapy with nucleoside analogues such as 
lamivudine or famciclovir  [9–11] . S-gene mutants can 
also be found accompanying mutations of the HBV poly-
merase gene, in patients receiving lamivudine treatment 
 [12] . It is however, not known whether the emergence of 
the S-gene mutants could alter the response to antiviral 
therapy.  
 The aims of the present study were to determine the 
profi le and frequency of naturally occurring S-gene muta-
tions and to investigate the frequency and signifi cance of 
S-gene mutants emerging due to long-term lamivudine 
therapy in patients with chronic hepatitis B. 
 Patients and Methods 
 Fifty-seven patients with histologically proven chronic liver dis-
ease due to HBV infection, fulfi lling the following criteria were 
included: (i) HBsAg positivity  1 6 months, (ii) elevated ALT ( 1 1.5 
times upper limit of normal), (iii) HBV DNA positive by a quanti-
tative DNA assay, (iv) lamivudine therapy for  6 24 months.  Exclu-
sion criteria : (i) infection with hepatitis C virus (anti-HCV and/or 
HCV RNA positive), hepatitis D virus (total anti-  positive), or 
HIV (HIV I and II positive), (ii) history of HBV vaccination, (iii) 
associated hepatocellular carcinoma or renal failure and (iv) re-
cipient of hyperimmune   -globulin. 
 Collection of Serum Samples 
 Serum samples from the patients were collected at baseline, 
month 1 and once at every 1–3 months (irregular intervals) subse-
quently. Sera were stored for molecular studies at –70  °  C. 
 Lamivudine Therapy 
 Lamivudine was given in a dose of 100 mg/day for  1 24 months. 
The patients were followed up regularly throughout the antiviral 
therapy. 
 DNA Extraction from Serum Samples 
 The DNA was extracted from 100   l of patient serum with the 
help of standard phenol/chloroform extraction method. Briefl y, 
100-  l serum samples were treated with 5   l proteinase K (15 mg/
ml), 10   l of 10 ! serum lysis buffer and 5   l of 20% SDS at 37  °  C 
for 3 h. Subsequently, the supernatant obtained after phenol, chlo-
roform and chloroform iso-amyl alcohol (24:  1) steps was left for 
overnight DNA precipitation in the presence of 3  M NaOAc, pH 
5.2, and absolute alcohol. After centrifugation, the obtained pellet 
was washed with 70% alcohol, dried, and, dissolved in 30   l of TE 
(10 m M Tris and 1 m M EDTA) buffer. 
 Nested Polymerase Chain Reaction Amplifi cation of HBV 
DNA 
 The region encoding the complete MHR along with the fl anking 
regions of surface protein (HBsAg) that overlapped with catalytic 
domains of P-ORF (nucleotide position, nt., 425–840 of the HBV 
genome) was amplifi ed by nested polymerase chain reaction (PCR). 
Three microliters of extracted DNA from serum samples were am-
plifi ed in a 25-  l reaction mixture containing dNTP, MgCl 2 , PCR 
buffer and Taq DNA polymerase in the appropriate quantity. The 
amplifi cation step was performed for 30 cycles with the outer prim-
ers SA1: 5  -ATCGC,TGGAT, GTGTC, TGCGG-3  and SA2: 5  -
GGCAA, CGGGG, TAAAG, GTTCA-3  (position 369–388 and 
1136–1155, respectively) in the HBV genome. Ten microliters of 
amplifi ed product were analyzed on 1.2% agarose gel in 1 ! TBE. 
Samples that did not show amplifi cation were directly used for 
nested amplifi cation. Where a 787-bp fragment was generated, 
nested PCR was done after appropriate dilution. Three microliters 
of the fi rst round PCR product (directly or after dilution depending 
on the band intensity visualized on the gel) were used as a template 
in a second amplifi cation step performed for 30 cycles with inner 
primers SB1: 5  -TTAGG, GTTTA, AATGT, ATACC, C-3  (posi-
tion 822–842) and SB2: 5  -CATCT, TCTTG, TTGGT, TCTTC, 
TG-3  (position 427–448). PCR was carried out using denaturation 
at 94  °  C for 1 min, annealing at 55  °  C for 1 min and primer exten-
sion at 72  °  C for 2 min for a total of 30 cycles and fi nally a single 
cycle for primer extension was carried out at 72  °  C for 7 min. Ten 
microliters of nested PCR product (416 bp) were analyzed by the 
agarose gel electrophoresis on 1.2% gel in 1 ! TBE buffer. In addi-
tion, all negative controls from the fi rst round of amplifi cation were 
included in the second amplifi cation step. Purifi ed HBV DNA from 
the recombinant vector pcf 80 (pBR322 having full-length HBV 
genome cloned at its  Eco RI site) was used as the positive control. 
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DNA extracted from serum samples of healthy controls and water 
were used as negative control. 
 Direct DNA Sequencing of the PCR Product 
 Purifi ed 416-bp fragment (with the help of PCR purifi cation kit, 
Qiagen) was sequenced with both forward and reverse primers (SB1 
and SB2, respectively) in an automated DNA sequencer (ABI 377-
18 sequencing system, Perkin Elmer). Briefl y, 200–250 ng of puri-
fi ed template in 5   l of volume were mixed with 4   l of sequencing 
reaction mixture supplied by Perkin-Elmer and 1   l each of the SB1 
and SB2 primers of 5 pmol/  l concentration in two different sets 
of reactions. Sequencing reaction was carried out under the cyclic 
conditions of 96  °  C for 30 s, 55  °  C for 30 s and 60  °  C for 4 min. Af-
ter completion of 30 cycles, the sequencing reaction product was 
precipitated by adding 90   l H 2 O, 10   l 3  M NaOAc (pH 4.6) and 
250   l absolute alcohol at room temperature for 10 min, and cen-
trifuged at 12,000 rpm for 15 min. Subsequently, 70% alcohol wash 
was given to the pellet at the same speed for 10 min, and at 37  °  C 
the dried pellet was dissolved in 3.5   l of gel-loading dye (for-
mamide and dextran blue). Samples were denatured for 10 min at 
90  °  C, and then quenched on ice for 5 min, prior to loading on poly-
acrylamide gel in the automated DNA sequencer. Obtained elec-
trophorograms were carefully read to repair the appearance of ‘N’ 
in the sequence and to ensure if the laser reader has correctly read 
the peaks in the electrophorograms. Obtained sequences were 
translated to amino acid sequences using the software ExPasy tool. 
Consensus amino acid sequences of known subgenotypes A1 and 
D2 from India  [13] were aligned with amino acid sequences of pa-
tients’ isolates using the ‘Multalin’ software. 
 Mutational Analysis 
 Presence of amino acids at a particular locus from the isolates 
of patients of this study, which was not found in the consensus 
amino acid sequences of Indian subgenotypes (A1 and D2) at that 
locus, was considered as the mutation/variation. 
 Viral DNA Quantitation 
 HBV DNA was quantifi ed using a liquid hybridization com-
mercial assay (Digene; lower limit of detection  ! 0.5 pg/ml of serum) 
in the serum obtained at baseline, month 1 and subsequently every 
1–3 months.  
 Response Assessment  [14] 
 End of Therapy Response (ETR).  In HBeAg-positive patients, 
it was defi ned as loss of HBeAg, loss of viral DNA ( ! 0.05 pg/ml) 
and normalization of ALT. In HBeAg-negative/anti-HBe-positive 
patients, however, it was defi ned as loss of viral DNA accompanied 
with the normalization of ALT. 
 Sustained Viral Response (SVR).  Persistence of the status of 
ETR for 6 months after stopping the therapy. 
 Non-Response.  Persistence of HBeAg and/or detectable levels 
of HBV DNA at the end of therapy/follow-up. 
 Drug Resistance.  Mutational analysis was done by direct DNA 
sequencing in the baseline and on-therapy samples. Mutations were 
also studied whenever the patients showed any biochemical de-
rangement or sudden rise in viral DNA. Drug resistance was diag-
nosed only when rtYM204I/VDD substitution within the viral 
polymerase was detected by direct DNA sequencing, irrespective 
of the viral DNA or ALT profi le at that time. 
 Results 
 Baseline Characteristics 
 All the 57 patients were positive for HBsAg, 32 were 
positive for HBeAg and 25 were HBeAg negative/anti-
HBe positive at baseline. In the 32 HBeAg-positive and 
in 25 anti-HBe-positive patients, the baseline HBV DNA 
was 1,478 (range, 9.5–9,000 pg/ml) and 827 pg/ml (range, 
2.4–9,166 pg/ml), respectively. Mean baseline ALT in 
HBeAg-positive and anti-HBe-positive patients was 80.4 
 8 28 and 107  8 36 IU/l, respectively ( table 1 ). 
 Response to Therapy 
 Of the 32 HBeAg-positive patients, loss of HBV DNA 
was achieved in 13 (41%) and loss of HBeAg and normal-
ization of ALT along with undetectable HBV DNA was 
observed in 8 (25%) patients. Thus, ETR was achieved in 
8 (25%) patients. SVR was achieved in 7 (22%) patients. 
One patient relapsed with HBeAg reappearance. Of the 
25 anti-HBe-positive patients, the ETR was seen in 12 
(48%) patients, and 10 (40%) patients maintained SVR 
at 6 months of follow-up. None of the 57 patients lost 
HBsAg during therapy or follow-up. 
 Naturally Occurring S-Gene Mutations 
 Only 2 of 57 (3.5%) patients had two different muta-
tions in their baseline samples. Both mutations were pres-
ent within the MHR of the S-gene: one at amino acid 
position 127 (sP127S) and another at 143 (sS143L) in an 
HBeAg-negative and an HBeAg-positive patient, respec-
Parameters
Patients 57
Males:females 51:6
Mean age, years
Males 37.5816.7
Females 39.2812.8
HBsAg positive 57
HBeAg positive 32
HBeAg negative/anti-HBe positive 25
Dose of lamivudine, mg/day 100; orally
Mean HBV DNA, pg/ml
HBeAg positive patients 1,478 (range 9.5–9000)
HBeAg negative patients 827 (range 2.4–9166)
Mean ALT, IU/l
HBeAg positive 80.4828
HBeAg negative 107836
Table 1. Demographic profi le and baseline characteristics of the 
patients
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Table 2. Naturally occurring surface and overlapping polymerase gene mutations
Patient
code
Nucleotide
change
Amino acid
substitution (HBsAg)
Corresponding change
in polymerase
HBeAg HBV
subgenotype
Diagnosis Response
to therapy
A27 C533T P127S S135F  – A1 DC no
A20 C582T S143 L F151F + D2 CHB no
CHB = Chronic hepatitis B; DC = decompensated cirrhosis.
 Fig. 1. Alignment of amino acid sequences from 101 till the last amino acid of HBsAg, i.e. aa 226, with the con-
sensus sequences of respective Indian subgenotypes A1 and D2  [13] among 16 patients harbouring S-gene muta-
tions in this study. Patients A20 and A27 had naturally occurring S-gene mutations and the remainder (14 patients) 
had lamivudine-associated S-gene mutations. 
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tively ( table 2 ). Both patients remained non-responsive 
to therapy. One HBeAg-negative patient harbouring a 
sP127S mutation developed decompensated cirrhosis. 
Corresponding amino acid substitution for sP127S was 
rtS135F, whereas sS143L substitution did not affect the 
overlapping polymerase sequence ( table 2 ). Amino acid 
sequence alignment for both these mutations is shown in 
 fi gure 1 with their respective subgenotype. 
 Lamivudine-Induced S-Gene Mutations 
 Upon analysis of the mutational profi le in samples ob-
tained during therapy, 16 different types of mutations 
were found emerging at varying time points in 14 of 57 
(24.5%) patients ( tables 3,  4 ). The S-gene mutations in-
cluded sP120S, sA128V, sS143L, sW182St., sT189I, 
sV190A, sS193L, sI195M, sW196L, sW196St., sS207R, 
sI208T, sS210E, sF219S, sF220L and sC221G ( table 3 ). 
Of the 16 types of mutations associated with lamivudine, 
only 3 (18.7%; sP120S, sA128V and sS143L) were no-
ticed within the MHR. The remainder (13 of 16; 81.2%) 
of the mutations emerged downstream to the MHR, sig-
nifi cantly more often in the region compared to the natu-
rally occurring mutations (p  ! 0.05). All the S-gene muta-
tions associated with lamivudine have been listed in  table 
3 along with the corresponding changes in polymerase. 
 Of the 57 patients, 8 developed a rtYM204I/VDD la-
mivudine-resistant polymerase mutant that in turn was 
associated with the surface gene mutants as sW196Stop, 
sI195M and sW196L in 1, 3 and 4 patients, respectively. 
In 1 of the 8 lamivudine-resistant patients, a unique and 
novel change of G to A at nt. 741 resulted in a non-sense 
mutation (sW196Stop) in the surface gene ( fi g. 1 ). Inter-
estingly, the same patient had another stop codon at aa 
182 (sW182St.) in the surface gene ( fi g. 1 ,  table 4 ), which 
was due to rtV191I substitution in the polymerase gene. 
This patient also developed hepatocellular carcinoma 
and died eventually ( table 4 ). 
 In a patient with decompensated liver disease, a cluster 
of mutations (sT189I, sV190A and sI208T) was found 
emerging due to prolonged lamivudine therapy. Interest-
ingly, none of these three mutations affected the poly-
merase reading frame ( table 3 ). The patient was HBeAg 
negative at baseline and did not respond to lamivudine 
with raised viral DNA level till his last visit. 
Table 3. Lamivudine-associated surface and overlapping polymerase gene mutations
Patient
code
Nucleotide
change
Amino acid
substitution 
(HBsAg)
Corresponding 
change in 
polymerase
HBeAg Time of 
emergence 
month
HBV
subgenotype
Response
to therapy
A15a C512T P120S T138I + 12 A1 no
A14
A43
C537T A128V C136C +
+
12
12
A1
D2
yes
no
A24 C582T S143L F151F + 12 D2 yes
A16 G700A W182Stop V191I + 16 D2 no
A36 C720T T189I H197H – 23 D2 no
A36 T723C V190A C198C – 23 D2 no
A15a C732T S193L F201F + 13 A1 no
A19
A46
A6
A739G I195M M204V +
+
–
18
30
26
A1
D2
D2
no
no
no
A10
A15a
A29
A56
G741T W196L M204I –
+
–
+
20
13
34
10
D2
A1
D2
D2
no
no
no
no
A16 G741A W196Stop M204I + 16 D2 no
A2
A6
A56
CA772,773TC S207R E215S. –
–
+
 8
26
10
A1
D2
D2
yes
no
no
A36 T777C I208T H216H – 23 D2 no
A45 GT783,784AG S210E S219A – 33 D2 no
A16 T810C F219S F227F + 16 D2 no
A10 TT814,815GG F220L & C221G L229G – 20 D2 no
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 Three types of double mutations emerged due to two 
consecutive nucleotide substitutions. One double muta-
tion at nt. positions 772 and 773 (CA to TC) resulted in 
change of glutamine to serine at aa 215 in the polymerase 
gene which, in turn, affected the surface gene as sS207R 
substitution. In 2 of the 3 patients harbouring the sS207R 
mutation, it emerged in association with lamivudine-re-
sistant mutant ( table 4 ). Another double mutation led to 
rtS219A change in the polymerase gene, which in turn 
resulted in a substitution of sS210E in the surface gene in 
an HBeAg-negative patient who never responded to the 
2-year course of lamivudine therapy. Mutations at nt. 814 
and 815 (TT to GG) were also found in a lamivudine-re-
sistant patient affecting both polymerase (rtL229G) and 
surface genes (sF220L and sC221G;  tables 3,  4 ). 
 A change of T to C at nucleotide position 810 resulted 
in sF219S substitution in a lamivudine-resistant patient, 
but this substitution was not due to any change in the 
polymerase gene ( table 3 ). 
 sW196L, sI195M, sS207R and sA128V were present 
in 4, 3, 3 and 2 patients, respectively, while the other la-
mivudine-associated mutations were found once in each 
patient ( table 3 ). 
 Overall, of the 16 types of S-gene mutations observed 
with lamivudine therapy, 9 (sP120S, sW182St., sI195M, 
sW196L, sW196St., sS207R, sS210E, sF220L and 
sC221G) mutations were associated with the changes oc-
curring in the polymerase gene, too ( table 3 ). 
 sS143L mutation was the only mutation which was 
noticed in the baseline sample of a patient ( table 2 ), and 
it also emerged in response to lamivudine therapy in an-
other patient ( table 3 ). All the other mutations were either 
present in the baseline sample or emerged after lamivu-
dine therapy. 
 S-Gene Mutations and Response to Therapy 
 Sixteen of 57 (28%) CHB patients receiving lamivu-
dine had surface and/or overlapping polymerase gene 
mutations, 2 (3.5%) patients had mutations at the base-
line while 14 (24.5%) developed these during the course 
of therapy. The remaining 41 (72%) patients always had 
wild-type surface and overlapping polymerase gene se-
quences. Seventeen of the 41 (41.5%) patients with wild-
type sequences responded to the lamivudine therapy, 
whereas only 3 of 16 (18.8%) patients harbouring S-/Pol-
gene mutation/s responded to lamivudine therapy (p  ! 
0.05;  table 5 ). The baseline viral DNA was signifi cantly 
higher in the patients who developed S-gene mutations 
(n = 16) compared with the other patients (n = 41; 2,093 
vs. 336 pg/ml;  table 5 ). Patients with polymerase gene 
Table 4. Accumulation of lamivudine-associated S-gene mutations in each individual along with HBeAg status, 
diagnosis and response to therapy
Patient 
No.
Patient
code
HBeAg Diagnosis HBV
subgenotype
Response
to therapy
Mutations
1 A2 – CHB A1 yes S207R
2 A6 – CHB D2 no I195M; S207R
3 A10 – CHB D2 no W196L; F220L; C221G
4 A14 + CHB A1 yes A128V
5 A15a + HCC (death) A1 no P120S; S193L; W196L
6 A16 + HCC (death) D2 no W182Stop; W196Stop; 
F219S
7 A19 + CHB A1 no I195M
8 A24 + CHB D2 yes S143L
9 A29 – CHB D2 no W196L
10 A36 – DC D2 no T189I; V190A; I208T
11 A43 + CHB D2 no A128V
12 A45 – CHB D2 no S210E
13 A46 + CHB D2 no I195M
14 A56 + DC D2 no W196L; S207R
Total: 14 patients HBeAg positive: 8 types of mutations: 16
HBeAg negative: 6
CHB = Chronic hepatitis B; DC = decompensated cirrhosis; HCC = hepatocellular carcinoma.
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mutations (n = 11) also had higher baseline viral DNA 
compared to those with wild-type polymerase gene (n = 
46; 2,205 vs. 337 pg/ml, p  ! 0.05). The aminotransferase 
levels were however comparable between the patients 
with and without S-gene mutations ( table 5 ).  
 Discussion 
 Therapy with lamivudine results in several mutations 
in the polymerase gene, some of which are associated with 
alterations in the ‘a’ determinant of HBsAg  [15] . These 
drug-resistant isolates may have the potential to become 
vaccine escape mutants. Following lamivudine therapy, 
a series of S-gene mutations were seen to emerge at vary-
ing time points in the present study. Fourteen of the 57 
(24.5%) patients on long-term lamivudine showed lami-
vudine-associated mutations. Since the ORF encoding 
HBsAg overlaps with that of the polymerase, mutations 
within the former may affect the latter or vice versa, with 
knock-on effect on viral replication  [16] . The interesting 
feature of mutations associated with prolonged lamivu-
dine therapy was their emergence downstream to the 
MHR. Only sP120S substitution emerged within MHR, 
but upstream to the ‘a’ determinant. This mutation has 
been found earlier in an immunized infant born to a 
chronic HBsAg-positive mother. Consistently, a de-
creased binding to the ‘a’ determinant-specifi c monoclo-
nal antibody was demonstrated for the HBsAg variant 
sP120S  [17] . 
 Recent reports show that even mutations emerging 
outside the MHR also lead to decreased antibody bind-
ing. It has been found that the sF183C mutation had de-
creased binding of the HBsAg to the ‘a’ determinant-spe-
cifi c antibody  [17] . In the light of these reports, emergence 
of mutations outside the MHR due to long-term lamivu-
dine therapy is a matter of serious concern, as signifi cant-
ly more mutations were found to develop downstream to 
the MHR in patients of the present study. 
 Few lamivudine-selected mutants occurring down-
stream to the MHR have been studied earlier. For in-
stance, sE164D, sW196S and sM198I showed reduced 
binding of HBsAg with the antibody. Moreover, sI195M 
has been shown to have moderately reduced binding of 
HBsAg with anti-HBs  [18] . In Indian patients undergoing 
lamivudine therapy, most frequently drug-selected sur-
face gene mutants are at aa 195 and 196. In agreement 
with earlier fi ndings, isoleucine at aa 195 was substituted 
with methionine, which may be responsible for moder-
ately reduced affi nity to bind anti-HBs in the process of 
Ag-Ab neutralization. The sI195M mutation was selected 
in 3 of our patients. Whereas, unlike the substitution of 
tryptophan with serine studied by Torresi et al.  [18] , in 
our patients, it was replaced with leucine in 4 patients and 
with a stop codon in 1 patient. We do not know the effect 
of the sW196L substitution on HBsAg binding with anti-
HBs. However, in view of HBsAg conformation stability, 
it is certain that any type of amino acid substitution with-
in aa 192–200 may alter the HBsAg-antiHBs binding af-
fi nity. At this conformational region, the HBsAg protein 
consists of two short   - helices separated by a disulphide 
bridge forming a turn  [19] . Sequence changes within this 
region may alter the structural integrity of the protein and 
may alter binding to anti-HBs antibody without affecting 
the assembly or secretion of the virus  [20] . In one of our 
patients within this region, tryptophan turned to be stop 
codon resulting in premature termination of the HBsAg. 
In the same patient, another stop codon mutation leading 
to premature termination of the HBsAg, 13 amino acids 
upstream, was also seen. Till now there are only a few re-
ports regarding the emergence of lamivudine-induced 
mutations which lead to premature termination of 
 HBsAg. In an in vitro cell culture system, Yeh et al.  [12] 
reported the coexistence of a stop codon (at aa 172) in 
the surface gene, severely impairing the secretion of 
HBsAg. Tillmann et al.  [21] reported the emergence of 
rtA181T polymerase mutant due to famciclovir therapy. 
With famciclovir therapy, a similar mutation at rtV207I 
in the ‘C’ domain of viral polymerase leading to a stop 
Patients with
S-gene mutations
(n = 16)
Patients without
S-gene mutations
(n = 41)
p value
DNA (baseline) 2,093 pg/ml 336 pg/ml <0.05
ALT (baseline) 99822 IU/l 93819 IU/l <NS
Response rate (ETR) 3 of 16 (18.8%) 17 of 41 (41.5%) <0.05
Table 5. Comparing the viral load, ALT 
and response rate between patients with 
and without S-gene mutations
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codon at aa 199 in overlapping surface protein was re-
ported  [22] . In all these patients, antiviral resistance and 
impaired secretion of HBsAg was shown in the in vitro 
culture system. In the present study, similar mutations 
were observed, but at novel loci, which resulted in the 
premature termination of HBsAg. Additionally, both the 
mutations (sW182Stop and sW196Stop) were in the same 
patient. The signifi cance of fi nding the HBsAg prema-
turely terminated at two different loci at an interval of 
12 aa is unclear. It is possible that these two mutations 
might be present in different viral populations. However, 
it is not clear why they emerged simultaneously. HBsAg 
positivity in this patient may be due to the mixed popula-
tion of the viruses having intact surface reading frame or 
due to the nuclear covalently closed circular DNA that 
remained wild type. 
 Insight into viral mutations has also come by exploring 
the regions of HLA class II-restricted epitopes within the 
entire HBsAg. Four class II-restricted epitopes within 
HBsAg have been described till date  [23] . Two of these 
lie downstream to the proposed MHR, and variations in 
these epitopes have been established to infl uence the T-
cell proliferation, antiHBc and IFN-  production in in 
vitro systems  [23] . 
 Within the recently proposed fourth epitope (aa 213–
226) also, three types of amino acid substitutions emerged 
in 2 of our patients, both of them received long-term la-
mivudine therapy but remained non-responders through-
out. sF219S emerged at month 16 in a patient and sF220L 
and sC221G emerged simultaneously at month 20 in an-
other patient. The sC221G mutant may be important as 
substitutions involving replacement or introduction of 
glycine or proline residues, which are   -helix breakers, 
may seriously affect secondary and tertiary structures of 
the HBsAg and impair the T-cell response  [23] . The in-
creasing use of antiviral agents, directed against the poly-
merase, could lead to new mutations in the molecule and 
in HBsAg, as sequences of these two molecules are par-
tially identical  [22, 24, 25] . 
 During lamivudine therapy, 9 of the 16 mutations in 
the surface gene (sP120S, sW182St., sI195M, sW196L, 
sW196St., sS207R, sS210E, sF220L and sC221G) 
emerged due to changes occurring in the polymerase gene 
( table 3 ). The other 7 mutations (sA128V, sS143L, sT189I, 
sV190A, sS193L, sI208T and sF219S), though developed 
in patients who were on long-term lamivudine therapy, 
did not have associated changes in the polymerase read-
ing frame. 
 These mutations are signifi cantly associated with a de-
creased response rate as only 3 of the 16 (18.8%) S-gene 
mutant patients responded to therapy compared to 17 of 
41 (41.5%) patients with completely wild-type S-gene se-
quence at every point of time (p  ! 0.05). 
 In summary, lamivudine therapy led to emergence of 
signifi cantly more S-gene mutants compared to the natu-
rally occurring S-gene mutations (p  ! 0.05). Naturally oc-
curring mutations are restricted to the ‘a’-determinant 
region, whereas drug-associated mutations generally oc-
cur downstream to the MHR. Seven types of surface mu-
tations, which emerged during prolonged antiviral thera-
py, did not affect the polymerase region at all. Whether 
they emerged in response to therapy or under the immune 
selection pressure needs to be further investigated. Ad-
ditionally, whether the changes arising outside the MHR 
of HBsAg are contributing to the formation of antigenic 
epitopes of varying specifi city and if they are also affect-
ing the reactivity with anti-HBs is of considerable inter-
est. Mutations (sW182St. and sW196St.) resulting in pre-
mature S-gene termination should also be studied further 
as they may affect the processes involved in virion assem-
bly and surface antigen formation. Careful studies of the 
molecular epidemiology of hepatitis B variants arising 
due to prolonged usage of nucleoside and nucleotide ana-
logues should extensively be done before their widespread 
usage. 
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